Prostaglandin-endoperoxide synthase genesCOX1 andCOX2 — novel modifiers of disease severity in cystic fibrosis patients
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Cystic fibrosis (CF) is one of the most common autosomal recessive diseases among Caucasians caused by a mutation in theCFTR gene. However, the clinical outcome of CF pulmonary disease varies remarkably even in patients with the sameCFTR genotype. This has led to a search for genetic modifiers located outside theCFTR gene. The aim of this study was to evaluate the effect of functional variants in prostaglandin-endoperoxide synthase genes (COX1 andCOX2) on the severity of lung disease in CF patients. To the best of our knowledge, it is the first time when analysis ofCOX1 andCOX2 as potential CF modifiers is provided. The study included 94 CF patients homozygous for F508del mutation ofCFTR. To compare their clinical condition, several parameters were recorded, e.g. a unique clinical score: disease severity status (DSS). To analyse the effect of non-CFTR genetic polymorphisms on the clinical course of CF patients, the whole coding region ofCOX1 and selectedCOX2 polymorphisms were analysed. Statistical analysis of genotype-phenotype associations revealed a relationship between the heterozygosity status of identified polymorphisms and better lung function. These results mainly concernCOX2 polymorphisms: −765G>C and 8473T>C. TheCOX1 andCOX2 polymorphisms reducing COX protein levels had a positive effect on all analysed clinical parameters. This suggests an important role of these genes as protective modifiers of pulmonary disease in CF patients, due to inhibition of arachidonic acid conversion into prostaglandins, which probably reduces the inflammatory process.
- Boyle MP, 2007. Strategies for identifying modifier genes in cystic fibrosis. Proc Am Thorac Soc 4:52–57. CrossRef
- Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F, 2004. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235. CrossRef
- Clayton A, Knox AJ, 2006. COX-2: a link between airway inflammation and disordered chloride secretion in cystic fibrosis? Thorax 61:552–553. CrossRef
- Cutting GR, 2005. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 6:237–260. CrossRef
- Davies J, Alton E, Griesenbach U, 2005. Cystic fibrosis modifier genes. J R Soc Med 98 Suppl 45:47–54.
- Davies JC, Griesenbach U, Alton E, 2005. Modifier genes in cystic fibrosis. Pediatr Pulmonol 39:383–391. CrossRef
- Davis PB, 2001. Cystic fibrosis. Pediatr Rev 22:257–264. CrossRef
- Drumm ML, 2001. Modifier genes and variation in cystic fibrosis. Respir Res 2:125–128. CrossRef
- Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, et al. 2005; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:1443–1453. CrossRef
- Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA, 2001. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468–476.
- Haston CK, Hudson TJ, 2005. Finding genetic modifiers of cystic fibrosis. N Engl J Med 353:1509–1511. CrossRef
- Hollox EJ, Davies J, Griesenbach U, Burgess J, Alton EW, Armour JA, 2005. Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis. J Negat Results Biomed 4:9–13. CrossRef
- Hull J, Thomson AH, 1998. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 53:1018–1021. CrossRef
- Katz SL, Strug LJ, Coates AL, Corey M, 2004. Disease severity in siblings with cystic fibrosis. Pediatr Pulmonol 37:407–412. CrossRef
- Knowles MR, 2006. Gene modifiers of lung disease. Curr Opin Pulm Med 12:416–421. CrossRef
- Konstan MW, Byard PJ, Hoppel CL, Davis PB, 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332:848–854. CrossRef
- Konstan MW, Schluchter MD, Xue W, Davis PB, 2007. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176:1084–1089. CrossRef
- Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O’Brien J, et al. 2005. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3:2340–2345. CrossRef
- Martin CP, Talbert RL, 2005. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy 25:942–953. CrossRef
- Merlo CA, Boyle MP, 2003. Modifier genes in cystic fibrosis lung disease. J Lab Clin Med 141:237–241. CrossRef
- Miller SA, Dykes DD, Polesky HF, 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215. CrossRef
- Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ, 2002. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. 22:1631–1636.
- Roca-Ferrer J, Pujols L, Gartner S, Moreno A, Pumarola F, Mullol J, et al. 2006. Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 61:592–596. CrossRef
- Salvatore F, Scudiero O, Castaldo G, 2002. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. 111:88–95.
- Sanak M, Szczeklik W, Szczeklik A, 2005. Association of COX-2 gene haplotypes with prostaglandin production in bronchial asthma. J Allergy Clin Immunol 116:221–223. CrossRef
- Slieker MG, Sanders EA, Rijkers GT, Ruven HJ, van der Ent CK, 2005. Disease modifying genes in cystic fibrosis. J Cyst Fibros 4 Suppl 2:7–13. CrossRef
- Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O, 2005. A genetic polymorphism in prostaglandin synthase 2 (8473, T→C) and the risk of lung cancer.Cancer Lett 226(1):49–54. CrossRef
- Szczeklik A, Sanak M, 2002. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp All 32:339–342. CrossRef
- Szczeklik W, Sanak M, Szczeklik A, 2004. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 114:248–253. CrossRef
- Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, Potter JD, 2002. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 20(5):409–410. CrossRef
- Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. 2004. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 13:889–893.
- Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, et al. 2007. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med, 175:1036–1043. CrossRef
- Welsh MJ, Smith AE, 1995. Cystic fibrosis. Sci Am 273:52–59. CrossRef
- Wine JJ, 1999: The genesis of cystic fibrosis lung disease. J Clin Invest 103:309–312. CrossRef
- Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, et al. 2005. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. 60: 320–325.
- Zielenski J, Tsui LC, 1995. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29:777–807. CrossRef
- Prostaglandin-endoperoxide synthase genesCOX1 andCOX2 — novel modifiers of disease severity in cystic fibrosis patients
Journal of Applied Genetics
Volume 51, Issue 3 , pp 323-330
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- cystic fibrosis
- lung disease
- gene modifiers
- Author Affiliations
- 1. Department of Medical Genetics, Institute of Mother and Child, Kasprzaka 17a, 01-211, Warsaw, Poland
- 2. Postgraduate School of Molecular Medicine, Warsaw, Poland
- 3. Department of Paediatrics, Institute of Mother and Child, Warsaw, Poland
- 4. Department of Biophysics, Institute of Biochemistry and Biophysics, Warsaw, Poland
- 5. Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, Ontario, Canada